| 000 | 01686nmm a22003617a 4500 | ||
|---|---|---|---|
| 003 | SPU | ||
| 005 | 20240325162942.0 | ||
| 008 | 240221s2022 enk|||||o|||| 00| 0 eng d | ||
| 020 | _a9781009278140 | ||
| 040 | _aSPU | ||
| 049 | _amain | ||
| 050 | 4 |
_aHD 9667.9.A78 _bT84F 2022 |
|
| 100 |
_aTulum, Oner _9256517 |
||
| 245 | 1 | 0 |
_aFrom financialisation to innovation in UK Big Pharma : AstraZeneca and GlaxoSmithKline / _cOner Tulum, Antonio Andreoni, William Lazonick |
| 260 |
_aCambridge : _bCambridge University Press, _c2022 |
||
| 300 | _aonline resource | ||
| 449 | _a110241 | ||
| 490 | 0 |
_aCambridge elements. Elements in reinventing capitalism 2634-8950 _x2634-8950 |
|
| 500 | _aTitle from publisher's bibliographic system (viewed on 30 Nov 2022) | ||
| 505 | _a1. Introduction -- 2. Innovation and Competition in the Global Pharmaceutical Industry -- 3. The Innovation-Financialisation Tension in the Global Pharmaceutical Industry -- 4. AstraZeneca -- 5. GlaxoSmithKline -- 6. Explaining the Financialisation-to-Innovation Transition at AstraZeneca and GlaxoSmithKline | ||
| 610 | 0 |
_aASTRAZENECA (FIRM) _xFINANCE _9256519 |
|
| 610 | 0 |
_aGLAXOSMITHKINE _xFINANCE _9256520 |
|
| 650 | 0 |
_aPHARMACEUTICAL INDUSTRY _zGreat Britain _xFINANCE _bGREAT BRITAIN |
|
| 650 | 0 |
_aBIOTECHNOLOGY INDUSTRY _zGREAT BRITAIN _xFINANCE _9256522 |
|
| 700 |
_aAndreoni, Antonio _9256523 |
||
| 700 |
_aLazonick, William _9256524 |
||
| 830 |
_9256518 _aCambridge elements. Elements in reinventing capitalism |
||
| 850 | _aSPU | ||
| 856 | _uhttps://doi.org/10.1017/9781009278140 | ||
| 910 |
_aLibrary _bCambridge University Press _c210224 _pEB000395 |
||
| 942 |
_2lcc _cEBK |
||
| 998 | _aniparat 0224 | ||
| 999 | _c213501 | ||